We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Guillermo A. Morales, PhD, MBA has 23 years of experience in chemistry and pharmaceutical R&D in positions of increasing responsibility (Director, CEO), devising and implementing strategic efforts for diverse research programs and therapeutics including cancer, CNS disorders, and anti-infectives.
Dr. Morales designed and discovered SignalRx’s compound classes from which diverse first-in-class inhibitors have emerged and are now being developed. He is also an entrepreneur with start-up co-founding experience, raising venture capital investment, leading and developing pharmaceutical programs from early drug discovery to IND ready.
Dr. Morales is the former Editor-in-Chief of the journal Molecular Diversity (11 years) and holds 11 patents (6 granted + 5 applications) and 33 publications.
Dr. Morales obtained his Ph.D. in Organic Chemistry from Louisiana State University and MBA from the Jack Welch Management Institute (Strayer University).
This speaker's sessions: